Therapeutics News and Research

RSS

Discovery opens doors to new therapies for sepsis

Despite numerous advances in treating infections and disease, effective treatments for sepsis remain elusive. A new discovery published in the June 2013 issue of The FASEB Journal not only could help health care providers predict who is more and less likely to develop sepsis, but it also opens the doors to new therapies that actually address the root cause of the problem, rather than just managing the symptoms.

31 May 2013

Safer, more effective treatment option for ovarian cancer

A novel, targeted approach to chemotherapy that makes ovarian cancer cells more susceptible to the cytotoxic effects of an antitumor drug may offer a safer, more effective treatment option for this often deadly form of cancer.

31 May 2013

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.

30 May 2013

Doctors perform investigational procedure on six patients using ADRCs to treat heart failure

Doctors at the Texas Heart Institute at St. Luke's Episcopal Hospital announced that they have performed an investigational procedure on six patients in a new FDA-approved clinical trial to evaluate therapy that uses regenerative cells derived from a patient's own adipose (body fat) tissue to treat a severe form of heart failure.

30 May 2013

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of a Phase 2b clinical study of TC-5214 as a treatment for overactive bladder.

29 May 2013

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Atopix Therapeutics Ltd, a biopharmaceutical company developing a novel class of anti-allergic medicines, has been awarded a £1.7 million grant from the UK Biomedical Catalyst fund to pursue development of OC459 in the treatment of moderate-to-severe atopic dermatitis (a form of eczema).

29 May 2013

Protein presenilin plays critical role in controlling neuronal traffic on microtubule highways

Imagine if you could open up your brain and look inside. What you would see is a network of nerve cells called neurons, each with its own internal highway system for transporting essential materials between different parts of the cell.

29 May 2013

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Acorda Therapeutics, Inc. will present new research data on AMPYRA (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis, being held in Orlando, FL, May 29 - June 1.

28 May 2013

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Sorrento Therapeutics, Inc. and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology.

28 May 2013

Researchers develop multicolor fluorescence labeling method to identify tumor specific miRNAs

In recent years, microRNAs and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers.

27 May 2013

Researchers discover how drug prevents cancer progression

In collaboration with Daniel Zenklusen, also a University of Montreal biochemistry professor and lead author and doctoral candidate Vincent Messier, discovered that when cells are starved for nutrients TOR sends a signal to shut down production of a chemical message in the form of RNA to synthesize B cyclin ", Dr. Michnick explained.

24 May 2013

Echo Therapeutics unveils Symphony CGM System

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the successful unveiling and demonstration of its Symphony CGM System during a live webcast following yesterday's annual stockholders meeting.

24 May 2013

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

23 May 2013

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

23 May 2013

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

Northwestern University researchers have developed a new method for delivering molecules into single, targeted cells through temporary holes in the cell surface. The technique could find applications in drug delivery, cell therapy, and related biological fields.

22 May 2013

Antidepressant treatment results in lower rate of MSIMI

Among patients with stable coronary heart disease and mental stress-induced myocardial ischemia (MSIMI), 6 weeks of treatment with the antidepressant escitalopram, compared with placebo, resulted in a lower rate of MSIMI, according to a study in the May 22/29 issue of JAMA.

22 May 2013

Caltech biologists show that microRNA-146a protects stem cells during inflammation

When infections occur in the body, stem cells in the blood often jump into action by multiplying and differentiating into mature immune cells that can fight off illness. But repeated infections and inflammation can deplete these cell populations, potentially leading to the development of serious blood conditions such as cancer.

22 May 2013

Clinical trial of Echo Therapeutics' Symphony CGM System receives IRB approval

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, announced today that the Company's clinical trial of its Symphony CGM System has received Institutional Review Board approval.

21 May 2013

Researchers develop new mouse model to discover gene pathways that drive MPNST

University of Minnesota Medical School researchers from the Masonic Cancer Center, University of Minnesota, in partnership with the University's Brain Tumor Program, have developed a new mouse model of malignant peripheral nerve sheath tumors that allow them to discover new genes and gene pathways driving this type of cancer.

21 May 2013

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Cell Therapeutics, Inc. today reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.

20 May 2013

Therapeutics News and Research

Discovery opens doors to new therapies for sepsis

Safer, more effective treatment option for ovarian cancer

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

Doctors perform investigational procedure on six patients using ADRCs to treat heart failure

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Protein presenilin plays critical role in controlling neuronal traffic on microtubule highways

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Researchers develop multicolor fluorescence labeling method to identify tumor specific miRNAs

Researchers discover how drug prevents cancer progression

Echo Therapeutics unveils Symphony CGM System

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

Antidepressant treatment results in lower rate of MSIMI

Caltech biologists show that microRNA-146a protects stem cells during inflammation

Clinical trial of Echo Therapeutics' Symphony CGM System receives IRB approval

Researchers develop new mouse model to discover gene pathways that drive MPNST

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News